Canton Biologics (Hong Kong) Limited (Cantonbio HK) is a biotechnology start-up established in 2023 in Hong Kong, dedicated to the discovery and development of innovative therapeutic biologics in aging and regenerative medicine. The company operates as a wholly owned subsidiary of Guangzhou Canton Biologics, while functioning as an independent, innovation-focused R&D hub within the broader group structure.
Positioned to incubate proprietary products and enabling technology platforms, Cantonbio HK combines expertise in recombinant protein engineering, complex biologics development, and translational research. By integrating advanced expression systems with early-stage CMC strategy, the company is structured to efficiently advance promising biologic candidates from concept validation toward clinical development. Its mission is to translate frontier biological insights into scalable, clinically meaningful therapeutics addressing unmet needs in regenerative and aesthetic medicine.
Cantonbio HK is committed to building a differentiated biologics pipeline targeting tissue regeneration, anti-aging, and advanced therapeutic delivery. The company focuses on structurally complex human proteins and next-generation biologic platforms, including exosome-based systems, with an emphasis on scientific rigor and manufacturability from the outset.
Global demographic shifts—such as population aging and growing demand for regenerative and aesthetic interventions—are reshaping healthcare priorities. Cantonbio HK addresses these trends through precision-engineered recombinant proteins and platform-driven innovation. By aligning discovery research with CMC feasibility and regulatory considerations at an early stage, the company aims to accelerate translational success while maintaining scalability for global markets.
Product
Cantonbio HK maintains four R&D programs, with CH001 and CH002 designated as strategic priorities. CH001 – Recombinant Human Hyaluronidase (rhuPH20) • Enzymatically degrades hyaluronic acid (HA). • Clinically applicable for correcting overcorrection and managing complications from HA-based dermal fillers. • Supports aesthetic and dermatological medical markets. CH002 – Recombinant Human Type III Collagen • Designed for wound healing, regenerative medicine, tissue engineering, and medical aesthetics. • Targets high-growth recombinant collagen markets with medical-grade, full-length bioengineered collagen. CH003 – Regenerative Therapeutic Protein • Demonstrates potential in wound repair and hair follicle neogenesis. • Under evaluation for indications including hair loss and tissue regeneration. CH004 – Exosome Platform • Focused on mesenchymal stem cell (MSC)-derived exosomes. • Aims to establish scalable production and purification systems. • Supports regenerative therapy and biologic drug delivery development.
Technology
1. Recombinant Collagen Platform for Aesthetic and Regenerative Medicine • Expression and CMC development of structurally complex human collagens. • Portfolio includes Type I, Type II, Type III, and Type XVII collagen. • Applicable to medical aesthetics, tissue repair, dermatology, and regenerative medicine. • Focused on structural integrity, bioactivity validation, and scalable GMP production. 2. Biologic Therapeutic Discovery and Evaluation Platform • Recombinant expression of challenging proteins. • Functional screening, mechanism-of-action studies, and preclinical evaluation. • Integrated analytical characterization aligned with regulatory standards. 3. Exosome Production and Purification Platform • Development of scalable, reproducible exosome manufacturing processes. • Advanced purification, characterization, and quality control systems. • Designed to support both regenerative therapeutics and drug delivery applications.
